250 related articles for article (PubMed ID: 8667046)
21. Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-Dopa PET in Parkinson's disease.
Vingerhoets FJ; Schulzer M; Ruth TJ; Holden JE; Snow BJ
J Nucl Med; 1996 Mar; 37(3):421-6. PubMed ID: 8772636
[TBL] [Abstract][Full Text] [Related]
22. 18F-FDOPA kinetics in brain tumors.
Schiepers C; Chen W; Cloughesy T; Dahlbom M; Huang SC
J Nucl Med; 2007 Oct; 48(10):1651-61. PubMed ID: 17873130
[TBL] [Abstract][Full Text] [Related]
23. Blood-brain transfer and metabolism of 6-[18F]fluoro-L-dopa in rat.
Reith J; Dyve S; Kuwabara H; Guttman M; Diksic M; Gjedde A
J Cereb Blood Flow Metab; 1990 Sep; 10(5):707-19. PubMed ID: 2117017
[TBL] [Abstract][Full Text] [Related]
24. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
[TBL] [Abstract][Full Text] [Related]
25. Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies.
Nagano-Saito A; Kato T; Arahata Y; Washimi Y; Nakamura A; Abe Y; Yamada T; Iwai K; Hatano K; Kawasumi Y; Kachi T; Dagher A; Ito K
Neuroimage; 2004 Jun; 22(2):553-61. PubMed ID: 15193583
[TBL] [Abstract][Full Text] [Related]
26. 6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures.
Barrio JR; Huang SC; Melega WP; Yu DC; Hoffman JM; Schneider JS; Satyamurthy N; Mazziotta JC; Phelps ME
J Neurosci Res; 1990 Dec; 27(4):487-93. PubMed ID: 2127807
[TBL] [Abstract][Full Text] [Related]
27. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study.
Rakshi JS; Uema T; Ito K; Bailey DL; Morrish PK; Ashburner J; Dagher A; Jenkins IH; Friston KJ; Brooks DJ
Brain; 1999 Sep; 122 ( Pt 9)():1637-50. PubMed ID: 10468504
[TBL] [Abstract][Full Text] [Related]
28. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.
Sawle GV; Burn DJ; Morrish PK; Lammertsma AA; Snow BJ; Luthra S; Osman S; Brooks DJ
Neurology; 1994 Jul; 44(7):1292-7. PubMed ID: 8035933
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and evaluation of an 18F-labeled dopa prodrug as a PET tracer for studying brain dopamine metabolism.
Ishiwata K; Shinoda M; Ishii S; Nozaki T; Senda M
Nucl Med Biol; 1996 Apr; 23(3):295-301. PubMed ID: 8782240
[TBL] [Abstract][Full Text] [Related]
30. Human striatal L-dopa decarboxylase activity estimated in vivo using 6-[18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects.
Kuwabara H; Cumming P; Reith J; Léger G; Diksic M; Evans AC; Gjedde A
J Cereb Blood Flow Metab; 1993 Jan; 13(1):43-56. PubMed ID: 8417009
[TBL] [Abstract][Full Text] [Related]
31. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies.
Eidelberg D; Moeller JR; Dhawan V; Sidtis JJ; Ginos JZ; Strother SC; Cedarbaum J; Greene P; Fahn S; Rottenberg DA
Mov Disord; 1990; 5(3):203-13. PubMed ID: 2117706
[TBL] [Abstract][Full Text] [Related]
32. Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease.
Gallagher CL; Oakes TR; Johnson SC; Chung MK; Holden JE; Bendlin BB; McLaren DG; Xu G; Nickles RJ; Pyzalski R; DeJesus O; Brown WD
Mov Disord; 2011 Mar; 26(4):614-20. PubMed ID: 21449008
[TBL] [Abstract][Full Text] [Related]
33. 6-fluoroDOPA metabolism in rat striatum: time course of extracellular metabolites.
DeJesus OT; Haaparanta M; Solin O; Nickles RJ
Brain Res; 2000 Sep; 877(1):31-6. PubMed ID: 10980240
[TBL] [Abstract][Full Text] [Related]
34. Distribution volume of 3-O-methyl-6.
Stout DB; Huang SC; Namavari M; Satyamurthy N; Yee RE; Barrio JR
J Cereb Blood Flow Metab; 2000 Dec; 20(12):1717-24. PubMed ID: 11129788
[TBL] [Abstract][Full Text] [Related]
35. A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease.
Li CT; Palotti M; Holden JE; Oh J; Okonkwo O; Christian BT; Bendlin BB; Buyan-Dent L; Harding SJ; Stone CK; DeJesus OT; Nickles RJ; Gallagher CL
Synapse; 2014 Aug; 68(8):325-31. PubMed ID: 24710997
[TBL] [Abstract][Full Text] [Related]
36. PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches.
Kumakura Y; Cumming P
Neuroscientist; 2009 Dec; 15(6):635-50. PubMed ID: 19793723
[TBL] [Abstract][Full Text] [Related]
37. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
Kumakura Y; Gjedde A; Danielsen EH; Christensen S; Cumming P
J Cereb Blood Flow Metab; 2006 Mar; 26(3):358-70. PubMed ID: 16079784
[TBL] [Abstract][Full Text] [Related]
38. Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease.
Ruottinen HM; Rinne JO; Ruotsalainen UH; Bergman JR; Oikonen VJ; Haaparanta MT; Solin OH; Laihinen AO; Rinne UK
J Neural Transm Park Dis Dement Sect; 1995; 10(2-3):91-106. PubMed ID: 9620057
[TBL] [Abstract][Full Text] [Related]
39. Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease.
Kaasinen V; Maguire RP; Hundemer HP; Leenders KL
J Neurol; 2006 Mar; 253(3):340-8. PubMed ID: 16222426
[TBL] [Abstract][Full Text] [Related]
40. PET studies of net blood-brain clearance of FDOPA to human brain: age-dependent decline of [18F]fluorodopamine storage capacity.
Kumakura Y; Vernaleken I; Gründer G; Bartenstein P; Gjedde A; Cumming P
J Cereb Blood Flow Metab; 2005 Jul; 25(7):807-19. PubMed ID: 15729292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
